Literature DB >> 9156050

Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour.

C S Mantzoros1, L J Suva, A C Moses, R Spark.   

Abstract

Hypercalcaemia, a common complication of malignancy, may result from either the lytic effect of multiple osseous metastases or the effect of tumour-derived humoral factors. Excessive secretion of parathyroid hormone-related peptide (PTHrP), a major cause of humoral hypercalcaemia of malignancy, has been incriminated as the cause of hypercalcaemia in patients with lung, breast, renal, head and neck and, occasionally, haematological malignancies. Carcinoid tumours, while frequently the source of ectopic hormone secretion, are infrequently associated with hypercalcaemia. We report the case of a 59-year-old woman with fulminant hypercalcaemia due to excessive PTHrP secretion from a hepatic carcinoid and we present the change in her serum PTHrP concentrations during infusion of a somatostatin analogue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156050     DOI: 10.1046/j.1365-2265.1997.1090921.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  A Case of Carcinoid Tumor-Associated Hypercalcemia.

Authors:  Fadi Siyam; Obai Abdullah; Michael Gardner; Stephen Brietzke; James Sowers
Journal:  Cardiorenal Med       Date:  2012-01-26       Impact factor: 2.041

Review 3.  Established and potential therapeutic applications of octreotide in palliative care.

Authors:  Eric E Prommer
Journal:  Support Care Cancer       Date:  2008-02-07       Impact factor: 3.603

4.  Management of the hormonal syndrome of neuroendocrine tumors.

Authors:  Paweł Gut; Joanna Waligórska-Stachura; Agata Czarnywojtek; Nadia Sawicka-Gutaj; Maciej Bączyk; Katarzyna Ziemnicka; Jakub Fischbach; Kosma Woliński; Jarosław Kaznowski; Elżbieta Wrotkowska; Marek Ruchała
Journal:  Arch Med Sci       Date:  2016-06-01       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.